Abivax
Company Details
Status: Public
Employees: 101-250
Location:
Paris, France
Type:
sample
sample
Technology:
sample
sample
sample
About: Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax is currently evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. Abivax also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease. Obefazimod is a potential first-line advanced therapy for moderately to severely active ulcerative colitis designed to enhance the expression of a single micro-RNA, miR-124, which is a natural regulator of the immune response. Abivax’s focus is on indications where existing treatments have left patients with significant unmet needs, and where they believe their drug candidates have the potential to be meaningfully differentiated from currently available therapies.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Abivax | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.